PARIS, May 6 — ExonHit Therapeutics S.A. (Alternext: ALEHT), a drug and diagnostic discovery company, announces today the availability of its new SpliceArray(TM) for use in disease modeling and toxicogenomic applications by the basic and pre-clinical research communities. These SpliceArray(TM) products provide the highest resolution expression profiling analysis for the rat genome commercially available today. ExonHit’s patented unique approach to detect all known and novel expressed transcripts is now offered through our portfolio of genomic services.
The Rat SpliceArray(TM) monitors over 23,000 genes utilizing over 200,000 exon body and 180,000 splice junction regions. This comprehensive coverage enables investigators to further elucidate the enormous diversity of the rat transcriptome. These new designs, manufactured on the Agilent Technologies and Affymetrix microarray platforms, now expand our product offering and enable researchers to leverage alternative splicing discovery in the rat model system.
“ExonHit continues to grow its catalog of arrays for it genomics services. This most recent addition will expand our ability to service clients who use rat models in elucidating disease biology, as well as for ExonHit’s discovery collaboration programs for therapeutic targets and safety biomarkers,” said John R. Jaskowiak, Executive Vice President of Molecular Diagnostics and Genomics Services at ExonHit Therapeutics. “The addition of this model organism to the SpliceArray(TM) product family further expands our presence in the expression profiling market. We strongly believe that these new SpliceArray(TM) products will further accelerate the understanding of mechanism of actions and ultimately the discovery of new therapeutics while providing unprecedented toxicogenomics data,” stated Philippe Rousseau, Chairman of the Executive Board of ExonHit Therapeutics. “Additionally, recent peer-reviewed publications in Cancer Research and Proceedings of the National Academy of Sciences further validate our high resolution approach to expression profiling.” About ExonHit Therapeutics
ExonHit Therapeutics is the world’s leader in the analysis of alternative RNA splicing, a process which when deregulated plays a key role in the onset of various diseases.
ExonHit has a multi-component commercial strategy to capture the maximum value from its leadership in alternative splicing. The Company is already generating revenues from a new generation of microarrays, SpliceArray(TM) family of products, that enable life science researchers to detect crucial disease-associated information. These products are marketed worldwide in conjunction with Agilent and Affymetrix. In the field of diagnostics, ExonHit has a major collaboration with bioMerieux to develop completely novel predictive blood-based cancer diagnostics, which could play a key role in improving the treatment of breast cancer and other major cancers.
In parallel, ExonHit is developing its own therapeutic pipeline in the field of neurodegenerative diseases and cancer. The Company has advanced drug candidates into clinical trials and is evaluating several promising pre-clinical compounds. ExonHit also has a strategic partnership with Allergan, to discover and develop new therapeutics in the areas of pain, neurological diseases and ophthalmology. This collaboration provides on-going research funding to ExonHit.
Founded in 1997, ExonHit is headquartered in Paris, France and has a U.S. facility in Gaithersburg, Maryland. The Company is listed on Alternext of Euronext Paris (ticker: ALEHT; ISIN: FR0004054427) since November 17, 2005.
This press release includes only summary information and does not purport to be comprehensive. The projections, forecast and estimates of ExonHit Therapeutics which may be contained herein are for illustrative purposes only and are based on management’s current views and assumptions. Such projections, forecast and estimates involve known and unknown risks and uncertainties, as described at Section 4.2 “Facteurs de risque” (Risk Factors) of the Document de Base available on ExonHit Therapeutics’ website (http://www.exonhit.com), that may cause actual results, performance or events to differ materially from those anticipated in the summary information.
In addition, ExonHit Therapeutics, its shareholders, and its affiliates, directors, officers, advisors and employees have not verified the accuracy of, and make no representations or warranties in relation to, statistical data or predictions contained in this press release that were taken or derived from third party sources or industry publications, and such statistical data and predictions are used in this press release for information purposes only.